Albany, New York, July 12, 2018: Presently, the Parkinson’s disease therapeutics market is experiencing relatively high growth due to rise in awareness concerning Parkinson’s disease as well as rapidly growing geriatric population, encouraging pipeline drugs, and fresh product launches. To study the overall market for Parkinson’s disease therapeutics, a new research report has been added to the broad database of Market Research Reports Search Engine (MRRSE). The analysis is titled “Parkinson’s Disease Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025”, which discourses the current as well as future prospects associated to the global market. According to active research findings, the global Parkinson’s disease therapeutics market acquired US$ 2.18 Bn in 2016 and is estimated to witness swelling annual growth at 10.9% CAGR during the period between 2017 and 2025. During the mentioned forecast period, the target market is likely to exhibit revenues higher than US$ 5.24 Bn.
According to research specifics, high prevalence along with rise in incidence rates of Parkinson’s disease across developed countries is acting as a driving factor for the global Parkinson’s disease therapeutics market. Also, high clinical R&D budget initiated by the governments as well as non-profit organizations are likely to fuel the growth of the overall market during the forecast period. The research report offers an elaborate executive summary merged with market snapshot detailing overall information focusing on the various segments reflected in the scope of the study.
The following section of the report discusses the various market segments such as drug class, distribution channel, route of administration and geography. On the basis of drug class, the global Parkinson’s disease therapeutics market is segmented into dopamine agonists, Levodopa combination, COMT Inhibitors, MAO-B Inhibitors and others. Based on route of administration, the market is bifurcated into oral, intestinal infusion, subcutaneous, transdermal and others. It is interesting to know that, the Parkinson’s disease therapeutics market is also analyzed by stressing on the distribution channel; based on this the market is classified retail pharmacy, hospital pharmacy and online pharmacy.
Geographically, Parkinson’s disease therapeutics market is divided into five major regions, namely, North America, Asia Pacific, Europe, Middle East & Africa and Latin America. Among these, Europe managed to acquire the largest share from the global Parkinson’s disease therapeutics market in the year 2016, trailed by North America that also held a substantial market share. Some of the leading players functioning in the global Parkinson’s disease therapeutics market are F. Hoffmann-La Roche AG, Novartis AG, AbbVie Inc., UCB Inc. and Teva Pharmaceutical Industries Ltd.
Browse Full Global Parkinson’s Disease Therapeutics Market Report with TOC : https://www.mrrse.com/parkinsons-disease-therapeutics-market
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY – 12207